Skip to main content
. 2023 Oct 1;37(19-20):913–928. doi: 10.1101/gad.351085.123

Figure 1.

Figure 1.

Generation of human cancer cells expressing degradable FKBP-WRN. (A) Schematics of the FKBP-WRN degron system. (E3) Cellular E3 ubiquitin ligase (CRBN in the case of dTAG-13). (B) Targeting strategy to achieve knock-in of FKBP-WRN at the endogenous human WRN locus. (C) Immunoblotting confirming successful knock-in of FKBP-WRN in human cancer cell lines treated or not with 0.5 μM dTAG-13 for 24 h. One of two independent experiments is shown. (D) Viability of FKBP-WRN-expressing human cancer cell lines treated or not with 0.5 μM dTAG-13 for 6 d. Where indicated, shWRN expression was induced with 1 μg/mL doxycycline (DOX). Average (±SD) of three independent experiments is shown. (E) Immunoblotting comparing the kinetics of dTAG-induced FKBP-WRN degradation with that of shWRN-induced WRN depletion. One of two independent experiments is shown.